Zacks: Invivo Therapeutics Holdings Corp (NVIV) Receives Consensus Rating of “Strong Buy” from Analysts
Shares of Invivo Therapeutics Holdings Corp (NASDAQ:NVIV) have been given an average broker rating score of 1.00 (Strong Buy) from the one analysts that provide coverage for the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a strong buy recommendation. Invivo Therapeutics’ rating score has improved by 50% from three months ago as a result of a number of analysts’ ratings changes.
Brokerages have set a 12 month consensus price target of $118.75 for the company, according to Zacks. Zacks has also assigned Invivo Therapeutics an industry rank of 177 out of 255 based on the ratings given to its competitors.
Separately, ValuEngine raised Invivo Therapeutics from a “hold” rating to a “buy” rating in a research report on Wednesday, April 18th.
Invivo Therapeutics (NASDAQ:NVIV) last posted its quarterly earnings results on Monday, May 7th. The biotechnology company reported ($3.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($3.25) by ($0.09). equities research analysts predict that Invivo Therapeutics will post -12.75 EPS for the current year.
Invivo Therapeutics Company Profile
InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries. It is developing Neuro-Spinal Scaffold implant, an investigational bioresorbable polymer scaffold for implantation at the site of injury within a spinal cord.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Invivo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invivo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.